Human Tissue Authority Launches Strategy for 2024-2027

The Human Tissue Authority (HTA) has today published its strategy for 2024-2027, setting out its vision and priorities for regulating the use of human tissue over the next three years.

Key Points:

• The strategy focuses on maintaining public trust and confidence in the safe handling of human tissue, cells and organs.
• Four strategic priorities are outlined: approach to regulation, trust and confidence, use of information, and efficiency and effectiveness.
• The HTA aims to be a more outcome-focused and proportionate regulator, using data and intelligence to target resources.
• There is an emphasis on collaboration with stakeholders and supporting innovation in the life sciences sector.
• The strategy reaffirms core principles of consent, dignity, quality, honesty and openness.

Lynne Berry CBE, Chair of the HTA, said:

"Over the next three years, we anticipate changes and opportunities for growth across the sectors we regulate. Our strategy positions us to support innovation through a proportionate and collaborative approach to regulation."

Dr Colin Sullivan, Chief Executive of the HTA, commented:

"This new strategy reflects our journey as a flexible and responsive regulator. We aim to maintain trust and confidence while supporting licensed establishments to deliver safe care with dignity and respect."

Background:

The HTA is the independent regulator for organisations that remove, store and use human tissue for research, medical treatment, post-mortem examination, education and training, and public display. It also approves organ and bone marrow donations from living people.

The full strategy document is available here: HTA strategy 2024 to 2027 | Human Tissue Authority